aprott
The Associated Press reports:
- Like the lives of the people taking them, recent injected drugs like Wegovy and its predecessor, the diabetes medication Ozempic, are reshaping the U.S. health and fitness industries. They have proven successful in eliminating unwanted pounds more quickly and easily than consuming fewer and burning more calories alone. Such is their disruptive power that even established diet companies like WeightWatchers (NASDAQ:WW) and brands like Lean Cuisine are getting makeovers.
- At least 3 million prescriptions for the class of medications known as GLP-1 agonists were issued each month in the U.S. during the 12 months that ended in March, according to data from health technology company IQVIA. They include semaglutide, the drug in Ozempic and Wegovy (NVO), and tirzepatide, the drug in Mounjaro and Zepbound (NYSE:LLY). Morgan Stanley research analysts have estimated that 24 million people, or 7% of the U.S. population, will be using GLPT-1 drugs by 2035.
- The world’s leading diet programs have taken note of such statistics and incorporated the popular drugs into their existing subscription plans.
- Read the full story.
